{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:59:09Z","timestamp":1783641549107,"version":"3.55.0"},"reference-count":24,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"Chia Tai Tianqing Pharmaceutical Group Co.,Ltd"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1080\/14712598.2021.1944097","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T05:07:25Z","timestamp":1623906445000},"page":"225-234","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira\u00ae in healthy Chinese male volunteers"],"prefix":"10.1080","volume":"22","author":[{"given":"Yanli","family":"Wang","sequence":"first","affiliation":[{"name":"Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyue","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co.,Ltd, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzhi","family":"Liu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwen","family":"Liu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Qu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Chen","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Experimental Pharmacology and Toxicology, School of Pharmacy, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongnan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co.,Ltd, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14330"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20187927"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.113039"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170817152554"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines4030014"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011941"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2003.10.002"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2019-0950"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13245"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000496453"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl19137"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12279"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2016.1255724"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1307339"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13039"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12583"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.380"},{"key":"e_1_3_7_20_1","unstructured":"Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product. [cited 2015 Apr]. Available from: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/blr.2011.9970"},{"key":"e_1_3_7_22_1","article-title":"A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects","author":"Cao GY","year":"2020","unstructured":"Cao GY, Yu JC, Wu JF, et al. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects. Clin Pharm Drug Dev. 2020;10(3):317-325.","journal-title":"Clin Pharm Drug Dev"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1347635"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-020-00613-9"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.01.009"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12464"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2021.1944097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T05:15:17Z","timestamp":1721625317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2021.1944097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1080\/14712598.2021.1944097"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2021.1944097","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}